6EF4
Crystal structure of mouse PP2A Aalpha P179R mutant
Summary for 6EF4
| Entry DOI | 10.2210/pdb6ef4/pdb |
| Descriptor | Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (1 entity in total) |
| Functional Keywords | pp2a, aalpha, protein binding |
| Biological source | Mus musculus (Mouse) |
| Total number of polymer chains | 1 |
| Total formula weight | 65509.50 |
| Authors | |
| Primary citation | Taylor, S.E.,O'Connor, C.M.,Wang, Z.,Shen, G.,Song, H.,Leonard, D.,Sangodkar, J.,LaVasseur, C.,Avril, S.,Waggoner, S.,Zanotti, K.,Armstrong, A.J.,Nagel, C.,Resnick, K.,Singh, S.,Jackson, M.W.,Xu, W.,Haider, S.,DiFeo, A.,Narla, G. The Highly Recurrent PP2A A alpha-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis. Cancer Res., 79:4242-4257, 2019 Cited by PubMed Abstract: Somatic mutation of the protein phosphatase 2A (PP2A) Aα-subunit gene is highly prevalent in high-grade endometrial carcinoma. The structural, molecular, and biological basis by which the most recurrent endometrial carcinoma-specific mutation site P179 facilitates features of endometrial carcinoma malignancy has yet to be fully determined. Here, we used a series of structural, biochemical, and biological approaches to investigate the impact of the P179R missense mutation on PP2A function. Enhanced sampling molecular dynamics simulations showed that arginine-to-proline substitution at the P179 residue changes the protein's stable conformation profile. A crystal structure of the tumor-derived PP2A mutant revealed marked changes in A-subunit conformation. Binding to the PP2A catalytic subunit was significantly impaired, disrupting holoenzyme formation and enzymatic activity. Cancer cells were dependent on PP2A disruption for sustained tumorigenic potential, and restoration of wild-type Aα in a patient-derived P179R-mutant cell line restored enzyme function and significantly attenuated tumorigenesis and metastasis . Furthermore, small molecule-mediated therapeutic reactivation of PP2A significantly inhibited tumorigenicity . These outcomes implicate PP2A functional inactivation as a critical component of high-grade endometrial carcinoma disease pathogenesis. Moreover, they highlight PP2A reactivation as a potential therapeutic strategy for patients who harbor P179R mutations. SIGNIFICANCE: This study characterizes a highly recurrent, disease-specific PP2A mutation as a driver of endometrial carcinoma and a target for novel therapeutic development.. PubMed: 31142515DOI: 10.1158/0008-5472.CAN-19-0218 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (3.4 Å) |
Structure validation
Download full validation report
